Deltagen Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a DGEN research report →
About the company
Deltagen Inc. provides drug discovery tools and services to the biopharmaceutical industry. The company offers a suite of programs designed to enhance the efficiency of drug discovery, including access to biological models, as well as small-molecule and secreted protein drug targets.
- CEO
- Robert J. Driscoll
- IPO
- 2000
- HQ
- San Mateo, CA, US
Price Chart
- Market Cap
- $3.86K
- P/E
- 0.04
- P/S
- 0.01
- P/B
- 0.00
- EV/EBITDA
- 0.37
- Div Yield
- 0.00%
- Gross Margin
- 29.28%
- Op Margin
- 29.28%
- Net Margin
- 28.90%
- ROE
- 4.58%
- ROIC
- 4.42%
- Revenue
- $263.00K · -74.27%
- Net Income
- $76.00K · 101.72%
- EPS
- $0.00 · 0.00%
- Op Income
- $77.00K
- FCF YoY
- 0.00%
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 2.70
- Avg Volume
- 278.26K
Get TickerSpark's AI analysis on DGEN
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our DGEN coverage
Recent articles, reports, and earnings notes.
No research on DGEN yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate DGEN report →Similar companies
Peers in the same neighborhood.